News | July 04, 2007

FDA Clears Spectranetics to Market TURBO-Booster

July 5, 2007 – The FDA has cleared Spectranetics Corp. to market its TURBO-Booster product for the treatment of arterial stenoses and occlusions in the leg, a peripheral laser catheter that functions as a guiding catheter facilitating directed ablation of blockages in the main arteries at or above the knee.

The TURBO-Booster combined with Turbo elite laser catheters reportedly allows for removal of large amounts of plaque material within the SFA and popliteal arteries. The CELLO trial, the study conducted to provide data to FDA in support
of the 510(k) premarket notifications for the TURBO-Booster clearance, is a prospective registry that enrolled 61 patients at 16 centers in the U.S. The trial included patients with stenoses and occlusions that were greater than or equal to 70 percent and less than or equal to 100 percent of the vessel lumen within arteries four to seven millimeters in diameter. Three independent core labs analyzed the angiographic, intravascular ultrasound and duplex ultrasound data from the trial. The primary endpoints of the trial were the achievement of a minimum 20 percent reduction in the percent diameter stenosis post-laser compared to pre-intervention and major adverse events. The reduction in percent diameter stenosis following the use of the TURBO-Booster was 35 percent and there were no major adverse events reported through 30 days following the procedure. As a result, the primary endpoints were met. Further data included in the FDA submission showed a significant improvement in Rutherford scores and health assessment questionnaires at 30-days compared to pre-procedure.
"We believe approximately two-thirds of all endovascular procedures in the legs are in the larger diameter arteries above the knee,” said John G. Schulte, Spectranetics’ president and CEO. “We expect to complete the initial launch to our atherectomy account base of approximately 350 accounts within a period of four to five months.”
Spectranetics plans to initiate two clinical trials in 2007, one in the United States and one in Europe, to assess the effectiveness of the TURBO-Booster and existing peripheral atherectomy products for the treatment of in-stent restenosis.

For more information:

Related Content

Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter
News | Chronic Total Occlusion (CTO)| June 28, 2017
June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus...
Ra Medical Systems Receives FDA Clearance for New Peripheral Artery Disease Treatment
Technology | Atherectomy Devices| May 30, 2017
The U.S. Food and Drug Administration (FDA) announced that it has granted market clearance to Ra Medical Systems for...
Mercator MedSystems Announces First Enrollment in TANGO Trial for Below-the-Knee Vascular Disease
News | Peripheral Artery Disease (PAD)| April 27, 2017
Mercator MedSystems Inc. announced the first patient enrollment into the TANGO (Temsirolimus Adventitial Delivery to...
CSI recall for saline pump on its atherectomy system
News | Atherectomy Devices| April 19, 2017
Cardiovascular Systems Inc. (CSI) announced April 18 it had initiated a voluntary recall of its 7-10014 Saline Infusion...
Cardiovascular Systems Inc., CSI, ECLIPSE clinical trial, Diamondback 360 Coronary Orbital Atherectomy System, first subject enrolled
News | Atherectomy Devices| April 04, 2017
Cardiovascular Systems Inc., in partnership with the Cardiovascular Research Foundation (CRF), announced the first...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters| March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Technology | Radial Access| February 17, 2017
Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line...
Overlay Init